Topic Hub
124 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 124 of 124 clinical reviews.
A detailed head-to-head comparison of liraglutide and retatrutide across special populations including T2D, obesity, CKD, cardiovascular disease, and older adults. Includes trial data, dosing, and switching guidance.
Read clinical reviewA head-to-head clinical comparison of liraglutide and retatrutide for weight loss and metabolic health, including the evidence for combining them, the real risks of dual therapy, and when a switch makes more sense than stacking.
Read clinical reviewA head-to-head clinical comparison of liraglutide and retatrutide for long-term weight-loss durability, covering trial data, mechanisms, switching protocols, and who benefits most from each agent.
Read clinical reviewA detailed clinical comparison of liraglutide (Saxenda/Victoza) and retatrutide, covering trial data, real-world outcomes, weight loss, side effects, and when switching makes sense.
Read clinical reviewA head-to-head clinical comparison of liraglutide and retatrutide titration schedules, side-effect profiles, and weight-loss outcomes, with dosing tables and switching guidance from the HealthRX medical team.
Read clinical reviewA clinical comparison of liraglutide and retatrutide for weight loss and type 2 diabetes, including when to switch, what the evidence says, and how HealthRX providers approach treatment failure.
Read clinical reviewA head-to-head look at liraglutide and dulaglutide (Trulicity) across clinical trials and real-world studies, covering weight loss, HbA1c reduction, cardiovascular outcomes, tolerability, and when to switch.
Read clinical reviewA detailed clinical comparison of liraglutide and dulaglutide (Trulicity) across special populations including CKD, heart failure, obesity, older adults, and pregnancy considerations. Includes trial data, dosing, and switching guidance.
Read clinical reviewA clinical comparison of liraglutide and dulaglutide (Trulicity), covering whether combining them makes sense, how to switch between them, head-to-head efficacy data, and the real safety risks of dual GLP-1 use.
Read clinical reviewA head-to-head clinical comparison of liraglutide and dulaglutide (Trulicity) for long-term glycemic durability, weight loss, and cardiovascular outcomes. Reviewed by the HealthRX medical team.
Read clinical reviewA clinical comparison of liraglutide and dulaglutide (Trulicity) covering titration schedules, GI tolerability, weight loss, cardiovascular outcomes, and how to decide between the two.
Read clinical reviewA clinical comparison of liraglutide and dulaglutide (Trulicity) covering efficacy, side effects, and a step-by-step guide to switching when one GLP-1 receptor agonist stops working.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and liraglutide across special populations including type 2 diabetes, obesity, CKD, cardiovascular disease, and older adults. Includes trial data, dosing guidance, and switching criteria.
Read clinical reviewA head-to-head clinical comparison of tirzepatide (Mounjaro) and liraglutide, covering efficacy data, switching protocols, combination rationale, and safety risks, reviewed by the HealthRX medical team.
Read clinical reviewA head-to-head clinical comparison of tirzepatide (Mounjaro) and liraglutide on long-term weight loss and glycemic durability, drawing on SURPASS-2, SCALE Obesity, SURMOUNT-1, and real-world evidence.
Read clinical reviewA physician-reviewed, evidence-based comparison of tirzepatide (Mounjaro) and liraglutide across clinical trials and real-world data, covering weight loss, blood sugar control, side effects, cost, and when to switch.
Read clinical reviewA clinical comparison of Mounjaro (tirzepatide) and liraglutide covering titration schedules, GI tolerability, weight-loss outcomes, and when switching between them makes sense.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and liraglutide, covering efficacy data, mechanism differences, and a step-by-step protocol for switching when one agent stops working.
Read clinical reviewA head-to-head clinical comparison of tirzepatide (Mounjaro) and retatrutide, covering mechanism differences, trial data, switching rationale, combination risks, and what the evidence says about using both.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and retatrutide on long-term weight loss durability, mechanism differences, trial data, and when switching makes sense.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and retatrutide, covering trial data, real-world evidence, weight loss outcomes, side-effect profiles, and guidance on switching between the two agents.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and retatrutide titration schedules, GI tolerability, and weight-loss outcomes, with primary-source citations for every key claim.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and retatrutide for weight loss and type 2 diabetes, including evidence-based guidance on switching when one drug stops working.
Read clinical reviewA detailed head-to-head comparison of tirzepatide (Mounjaro) and oral semaglutide (Rybelsus) across special populations including CKD, heart failure, elderly, and those switching between therapies. Reviewed by the HealthRX medical team.
Read clinical reviewA head-to-head clinical comparison of Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) titration schedules, GI tolerability, efficacy, and switching guidance for patients and clinicians.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and oral semaglutide (Rybelsus), including why combining them is contraindicated, how each drug works, and how to decide which one to use or whether to switch.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and oral semaglutide (Rybelsus) for long-term durability of glycemic and weight response, drawing on SURPASS-2, PIONEER-4, and real-world evidence.
Read clinical reviewA head-to-head comparison of Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) using clinical trial data and real-world evidence, covering weight loss, A1C reduction, dosing, cost, and when to switch.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and oral semaglutide (Rybelsus) for type 2 diabetes, including what evidence says about switching between them when one stops working or causes intolerable side effects.
Read clinical reviewA detailed head-to-head comparison of tirzepatide (Mounjaro) and liraglutide 3 mg (Saxenda) across special populations including type 2 diabetes, cardiovascular disease, renal impairment, older adults, and women with PCOS. Backed by trial data and clinical guidelines.
Read clinical reviewA detailed, evidence-based comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) titration schedules, GI tolerability, and weight-loss outcomes to help patients and clinicians make informed decisions.
Read clinical reviewA clinical deep-dive comparing tirzepatide (Mounjaro) and liraglutide (Saxenda) for weight loss, examining whether combining or sequencing them makes sense, what the evidence shows, and how to switch safely.
Read clinical reviewA head-to-head clinical comparison of tirzepatide (Mounjaro) and liraglutide 3 mg (Saxenda) for long-term weight loss durability, covering trial data, real-world evidence, and switching guidance.
Read clinical reviewA head-to-head comparison of tirzepatide (Mounjaro) and liraglutide 3 mg (Saxenda) drawing on clinical trials, real-world registry data, and current guidelines to help patients and clinicians choose the right GLP-1 therapy.
Read clinical reviewA clinical guide comparing tirzepatide (Mounjaro) and liraglutide (Saxenda) for weight loss, including when to switch, how to transition safely, and what the trial data say about each drug's failure modes.
Read clinical reviewA detailed clinical comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) across special populations including older adults, patients with CKD, cardiovascular disease, and obesity, with trial data and dosing guidance.
Read clinical reviewA clinical deep-dive into tirzepatide (Mounjaro) vs dulaglutide (Trulicity), why combining them is contraindicated, when switching makes sense, and what head-to-head trial data actually show.
Read clinical reviewA head-to-head clinical comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) on long-term blood sugar control, weight loss durability, cardiovascular outcomes, and when switching between the two drugs makes sense.
Read clinical reviewA head-to-head comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) using SURPASS-2, REWIND, and real-world cohort data, covering weight loss, A1C reduction, cardiovascular outcomes, and practical switching guidance.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) covering titration schedules, GI tolerability, weight loss, and HbA1c outcomes to help patients and clinicians choose the right GLP-1 therapy.
Read clinical reviewA clinical comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) covering efficacy, failure modes, and step-by-step guidance on when and how to switch between them.
Read clinical reviewA detailed head-to-head comparison of semaglutide (Ozempic) and liraglutide across special populations including CKD, heart failure, elderly patients, and those considering a switch between agents.
Read clinical reviewA clinical deep-dive comparing semaglutide (Ozempic) and liraglutide, covering head-to-head trial data, the rationale and risks of combining both GLP-1 agonists, and a structured guide to switching between them.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) vs liraglutide on long-term weight loss and glycemic durability, covering head-to-head trial data, real-world switching evidence, and practical prescribing guidance.
Read clinical reviewA detailed, evidence-based comparison of semaglutide (Ozempic) and liraglutide on weight loss, A1c reduction, cardiovascular outcomes, and switching considerations, grounded in head-to-head trials and real-world data.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) and liraglutide titration schedules, GI side-effect profiles, weight loss outcomes, and switching protocols, reviewed by the HealthRX medical team.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) and liraglutide for weight loss and glycemic control, with evidence-based guidance on switching when one GLP-1 stops working.
Read clinical reviewA direct clinical comparison of semaglutide (Ozempic) and tirzepatide (Mounjaro) across special populations including patients with T2D, obesity, CKD, cardiovascular disease, and those switching between agents. Includes trial data, dosing guidance, and switching protocols.
Read clinical reviewA head-to-head comparison of Ozempic (semaglutide) and Mounjaro (tirzepatide) titration schedules, GI tolerability, weight loss outcomes, and switching protocols, reviewed by the HealthRX medical team.
Read clinical reviewA clinical deep-dive comparing semaglutide (Ozempic) and tirzepatide (Mounjaro), explaining why combining them is contraindicated, how to switch safely, and which drug wins on weight loss and glycemic control.
Read clinical reviewA head-to-head clinical comparison of semaglutide (Ozempic) and tirzepatide (Mounjaro) for long-term weight loss and glycemic durability, including trial data, real-world evidence, and switching guidance.
Read clinical reviewA detailed, citation-dense comparison of semaglutide (Ozempic) and tirzepatide (Mounjaro) drawing on head-to-head trials, large real-world cohorts, and current clinical guidelines to help you and your provider decide which GLP-1 therapy fits your situation.
Read clinical reviewA clinician-backed guide comparing Ozempic (semaglutide) and Mounjaro (tirzepatide) for weight loss and blood sugar control, including when and how to switch if your current GLP-1 medication stops working.
Read clinical reviewA detailed clinical comparison of semaglutide (Ozempic) and retatrutide across special populations including CKD, older adults, and those with obesity-related comorbidities, covering efficacy, safety, and switching considerations.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) and retatrutide, covering mechanism differences, head-to-head efficacy data, the rationale for sequential or combination use, and the real risks of stacking two GLP-1-based agents.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) and retatrutide for long-term weight loss and glycemic durability, covering trial data, receptor mechanisms, and switching considerations.
Read clinical reviewA head-to-head clinical breakdown of semaglutide (Ozempic) versus retatrutide, covering trial data, weight loss outcomes, cardiovascular evidence, side-effect profiles, and when switching may make sense.
Read clinical reviewA clinical comparison of Ozempic (semaglutide) and retatrutide titration protocols, GI tolerability, and weight-loss outcomes, reviewed by the HealthRX medical team.
Read clinical reviewA clinical comparison of semaglutide (Ozempic) and retatrutide for weight loss and type 2 diabetes, including what the evidence says about switching when one drug stops working.
Read clinical reviewA thorough clinical comparison of injectable semaglutide (Ozempic) and oral semaglutide (Rybelsus) across special populations including CKD, elderly patients, obesity, and cardiovascular disease, based on SUSTAIN-7, PIONEER-4, and real-world evidence.
Read clinical reviewShowing the first 60 matches. Use search or filters to narrow the library.